According to a recent LinkedIn post from SeqOne, the company participated in a workshop in Lisbon focused on helping Hospital de Santa Maria build a clinical next-generation sequencing, or NGS, facility from the ground up. The event, organized by distributor Soquimica alongside PacBio and Agilent Technologies, appears to have covered the full workflow from sample preparation to clinical reporting.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post highlights that PacBio’s contribution centered on long-read versus short-read sequencing and the case for standardizing long-reads in routine diagnostics, while Agilent focused on sample quality control and accurate variant detection. SeqOne’s role was described as converting sequencing data into structured clinical reports across germline, oncology, and infectious disease applications.
The content suggests growing interest from large hospital laboratories in scaling in-house NGS diagnostics rather than outsourcing, with Portuguese clinicians reportedly focused on how to scale adoption rather than whether to adopt it. For SeqOne, deeper engagement in hospital-based workflows could support recurring software and analytics revenues and strengthen its positioning within the clinical genomics value chain.
Collaborations with established technology providers such as PacBio and Agilent may enhance SeqOne’s integration into end-to-end NGS solutions, potentially improving its visibility in key European healthcare markets like Portugal. If hospitals increasingly internalize genomic testing, vendors that provide robust reporting and interpretation capabilities could benefit from higher test volumes and long-term customer relationships, though pricing, regulatory, and reimbursement dynamics remain key external variables for investors to monitor.